Active, not recruitingEarly Phase 1NCT06148636
A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors
Studying Neuroendocrine tumor of pancreas
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- David Bushnell
- Principal Investigator
- David Bushnell, MDUniversity of Iowa
- Intervention
- [212Pb] VMT-α-NET(drug)
- Enrollment
- 24 enrolled
- Eligibility
- 18-80 years · All sexes
- Timeline
- 2023 – 2027
Study locations (1)
- Holden Comprehensive Cancer Center at the University of Iowa, Iowa City, Iowa, United States
Collaborators
Holden Comprehensive Cancer Center · National Cancer Institute (NCI) · Perspective Therapeutics
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06148636 on ClinicalTrials.govOther trials for Neuroendocrine tumor of pancreas
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07273409Pancreatic Neuroendocrine Tumour - Optimal Surgical Debulking or NotUppsala University
- ENROLLING BY INVITATIONPHASE2NCT07121478Patients With High-grade Pancreatic Neuroendocrine TumorsNational Cancer Center, Korea
- RECRUITINGPHASE2, PHASE3NCT06943755Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine TumorsExelixis
- RECRUITINGPHASE1NCT06663072Study to Test the Combination of Fulvestrant With Lu-DOTATATE for Advanced Pancreatic Neuroendocrine TumorsUniversity of Chicago
- RECRUITINGPHASE1NCT05687123Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine TumorsNational Cancer Institute (NCI)
- ACTIVE NOT RECRUITINGNCT06406387ATRX/DAXX in EUS-FNB Specimens of Pan-NETsAzienda Ospedaliera Universitaria Integrata Verona
- RECRUITINGNCT06121622Development of New Personalised 3D Preclinical Models of Pancreatic Neuroendocrine TumoursIRCCS San Raffaele
- RECRUITINGPHASE2NCT05997056Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR InhibitorsAadi Bioscience, Inc.